Navigation Links
Japanese Cancer Patients Will Have Access to Compensator-Based IMRT with Opening of .decimal, Inc. Office in Tokyo and Hiring of Key Personnel
Date:11/4/2009

SANFORD, Fla., April 13 /PRNewswire/ -- .decimal, Inc., leading manufacturer of patient-specific medical devices, opens their first international office in Tokyo, Japan. An office in Japan will further strengthen .decimal's commitment to the Japanese market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090203/CLTU104LOGO )

Richard Sweat, President/CEO of .decimal said, "The opening of an office in Japan is another example of our dedication to provide cancer patients around the world with innovative treatment solutions."

Japan is the second largest market in the world for medical devices and has a $20 billion medical device industry, with $5 billion in U.S. imports, according to the International Trade Administration. With an increasing number of patients with chronic diseases in Japan, medical devices to treat age-related diseases shows the potential for steady growth.

"After visiting Japan, meeting with medical universities and doctors and reviewing our market research, it was evident which market would be the next opportunity for us to grow globally. It is our understanding that there are over 700 radiation therapy centers and more than 1,000 full-time medical doctors in Japan - a substantial statistic," said Mark Mills, Senior Vice President of Sales and Marketing for .decimal. "We are excited to bring our products to market in Japan and we believe an authorized office is the appropriate next step."

.decimal will be providing cancer institutions in Japan the devices necessary to deliver compensator-based Intensity Modulated Radiation Therapy, an advanced form for delivering radiation. Compensators provide the maximum dose to the tumor, while providing maximum protection to the surrounding healthy tissues and organs, reducing the risk of acute and chronic damage. .decimal is in the process of being cleared by Japanese regulatory agencies and looks forward to begin offering their products commercially overseas.

"Cancer centers in Japan will soon have the opportunity to enhance their current radiation delivery capabilities through our unique pay-as-you-go, Internet-based manufacturing business model," said Sweat.

.decimal will be represented in Japan by Sam Tabuchi of Enterprise Florida-Japan. The .decimal office will be located at:

    Sagamiya #2 Building 5F
    10 Ichibancho
    Chiyoda-ku, Tokyo 102-0082
    Phone: 03-3230-0505

.decimal is a medical device manufacturer of patient-specific devices, including missing tissue compensators, modulators for advanced IMRT delivery, as well as apertures and range compensators used in proton therapy. The company has been providing radiation therapy products for over twenty years and serves more than 200 customers. For more information concerning .decimal, please see its Web site at www.dotdecimal.com.

SOURCE .decimal, Inc.


'/>"/>
SOURCE .decimal, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
3. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
4. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
5. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
6. BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):